肺癌，細胞凋亡，抗體:藥物開發策略分析 是由出版商BioSeeker Group AB在2011年12月所出版的。
這份英文市場調查報告書包含4884 Pages 價格從美金5175起跳。
本報告提供肺癌的藥物開發策略和以細胞凋亡的機制、目標、影響領域和抗體的化合物領域為焦點，彙整各自的藥劑目標策略，化合物策略競爭基準，開發平台及最佳投資組合計劃等等彙整，為您概述為以下內容。
第1章 肺癌
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的肺癌治療目標討論
- 新藥的上市:各開發階段肺癌治療藥物的藥劑目標策略
- 使用中的化合物策略:各類型化合物競爭基準
- 治療藥物的適應症選擇
- 開發平台·最佳投資組合計劃:肺癌治療藥物開發平台的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
- 圖表
第2章 細胞凋亡
- 本報告的範圍
- 為達成最高治療效果及投資報酬率治療目標檢討
- 新藥的上市:細胞凋亡治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:細胞凋亡藥物的各類型化合物的競爭基準
- 細胞凋亡的癌適應症症狀選擇
- 最佳投資組合計劃:細胞凋亡開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第3章 抗體
- 本報告的範圍
- 為達成最高治療效果及投資報酬率治療目標
- 新藥的上市:癌症的抗體治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 抗體治療藥物的癌適應症症狀的選擇
- 最佳投資組合計劃:癌症的抗體治療開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
Abstract
Product Description
This triple analysis focuses on cancer drug development strategies in one
specific cancer indication (Lung Cancer), one mechanism/target/effect area
(Apoptosis) and one compound specific area (Antibodies). Each of these three
individual parts is evaluated according to standardized criteria in a five
pillar pipeline drug assessment methodology to compare drug development
strategies in oncology. This makes it easy to find and compare analysis not
only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development
strategies for 416 lung cancer drugs within the portfolio of 218
investigators, from Ceased to Marketed. This part extensively analyses their
241 identified drug targets, organized into 237 drug target strategies, and
assesses them in eight different compound strategies and and three
subindications of lung cancer.
Part II: Apoptosis
The apoptosis report part comprises defined and up to date development
strategies for 171 apoptotic drugs in oncology (519 projects) within the
portfolio of 125 investigators, from Ceased to Pre-registration. This report
part extensively analyses 146 identified targets of apoptotic drugs, organized
into 120 drug target strategies, and assesses them in 53 different cancer
indications.
Part III: Antibodies
The antibody report part comprises defined and up to date development
strategies for 441 antibody drugs (993 projects) within the portfolio of 168
investigators, from Ceased to Marketed. This report part extensively analyses
225 identified targets of antibody drugs, organized into 234 drug target
strategies, and assesses them in 69 different cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Lung Cancer
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest
Therapeutic Outcome and Return on Investment (241 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target
Strategies and 416 Lung Cancer Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer
Drugs by Compound Strategy (8 Compound Strategies)
- 9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of
Lung Cancer)
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung
Cancer Drug Pipeline by Investigator (218 Companies)
- 11 Disclaimer
- 12 Drug Index
- 13 Company Index
Part II: Apoptosis
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (146 Drug Targets)
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic
Pipeline? (120 Drug Target Strategies and 171 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs
in Oncology by Compound Type (7 Different Compound Strategies)
- 9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer
Indications)
- 10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer
Therapeutic Pipeline by Investigator (125 Investigators)
- 12 Drug Index
- 13 Company Index
Part III: Antibodies
- 5.2 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (225 Drug Targets)
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Antibody Therapeutic
Pipeline? (234 Drug Target Strategies and 441 Drugs)
- 8 Selecting Cancer Indications for Antibody Therapeutics (69 Different
Cancer Indications)
- 9 Portfolio Planning: Competitive Benchmarking of Antibody Cancer
Therapeutic Pipeline by Investigator (168 Investigators)
- 11 Drug Index
- 12 Company Index
Featured Companies
This Report Includes the Following Companies:
- A&G Pharmaceutical
- Abbott
- Abiogen
- AC Immune
- Access
- Actinium Pharmaceuticals
- Active Biotech
- Adherex
- Advanced Life Sciences
- Advanomics
- Advantagene
- AEgera
- AEterna Zentaris
- Affibody
- Affimed Therapeutics
- Agennix
- Aida Pharmaceuticals
- Alchemia
- Alder Biopharmaceuticals
- Alethia Biotherapeutics
- Alexion
- Allos Therapeutics
- AlphaVax
- Altor BioScience
- Ambrilia Biopharma
- Amgen
- Anavex Life Sciences
- AngioChem
- Antisense Pharma
- Antisoma
- Anza Therapeutics
- Aphios
- ApopLogic Pharmaceuticals
- Apotex
- Arana Therapeutics
- Arca biopharma
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Astellas
- AstraZeneca
- Attenuon
- AVEO
- Avila Therapeutics
- Axelar
- Bayer
- Benitec
- Betapharma
- BioAxone
- Biocon
- Biogen Idec
- BioInvent
- Biokine Therapeutics
- Biolex
- BioLineRx
- Bionovo
- BioNumerik
- BioSante
- Biosceptre
- Biotecnol
- BioVex
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Calando Pharmaceuticals
- CanBas
- Cancer Research Technology
- Celator Pharmaceuticals
- Celgene
- Cell Therapeutics
- Celldex Therapeutics
- Celtic Pharma
- Center of Molecular Immunology
- Cephalon
- CG Therapeutics
- ChemoCentryx
- Chemokine Therapeutics
- Chong Kun Dang
- Circadian Technologies
- Clavis Pharma
- CLL Pharma
- Coronado Biosciences
- Critical Outcome Technologies
- CuraGen
- Curaxis
- CureTech
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- Cynvec
- CytImmune Sciences
- Cytochroma
- Cytokinetics
- CytRx
- Daewoong
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Dara Biosciences
- Dendreon
- Dong-A
- Dyax
- ECI
- Eisai
- Elan
- Elara Pharmaceuticals
- Eleos
- Eli Lilly
- Endocyte
- EntreMed
- Enzon
- EpiCept
- Exelixis
- Facet Biotech
- Favrille
- Five Prime Therapeutics
- Fresenius
- Galapagos
- GammaCan
- Gemin X Biotechnologies
- Genentech
- Genmab
- GenPat77
- Genta
- GenVec
- Genzyme
- Geron
- Gilead Sciences
- GlaxoSmithKline
- Gliknik
- GlobeImmune
- GlycoGenesys
- Gradalis
- Green Cross
- Hanmi
- Hoffmann-La Roche
- Human Genome Sciences
- Idera Pharmaceuticals
- IDM Pharma
- ImClone Systems
- ImmunoCellular Therapeutics
- Immunocore
- ImmunoGen
- Immunomedics
- ImmuPharma
- Incyte Corporation
- Infinity Pharmaceuticals
- Innate Pharma
- InNexus Biotechnology
- Innovive
- Inovio
- Insmed
- Insys Therapeutics
- Intezyne Technologies
- Intracel
- Intradigm
- Introgen Therapeutics
- Ipsen
- ISA Pharmaceuticals
- Isis Pharmaceuticals
- ISU ABXIS
- Jennerex Biotherapeutics
- Johnson & Johnson
- KaloBios
- Kalypsys
- Kiadis
- Kirin Pharma
- Kissei
- Kyowa Hakko Kirin
- LFB Biotechnologies
- Ligand
- Lorus Therapeutics
- MacroGenics
- Marillion Pharmaceuticals
- MAT Biopharma
- Meda
- Medarex
- MediGene
- MedImmune
- Medisyn Technologies
- Menarini
- Merck & Co
- Merck KGaA
- Merrimack
- Mersana Therapeutics
- MethylGene
- Micromet
- Mirna Therapeutics
- MolMed
- Mologen
- Mycenax
- Nektar Therapeutics
- NeoPharm
- Neovacs
- Nereus Pharmaceuticals
- Nerviano Medical Sciences
- Neurocrine Biosciences
- NewSouth Innovations
- NIH
- Nippon Kayaku
- Nippon Shinyaku
- Non-industrial source
- Northwest Biotherapeutics
- Novacea
- Novartis
- Novelix
- Novogen
- Oasmia
- OncoGenex Pharmaceuticals
- OncoMed
- Onconova
- Oncothyreon
- Onyvax
- Orchestra Therapeutics
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Paladin Labs
- PanaGin
- PBL Therapeutics
- Pepscan Therapeutics
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharmexa
- Pharminox
- Philogen
- Pierre Fabre
- Prima Biomed
- Pro-Pharmaceuticals
- Prochon Biotech
- Progen Pharmaceuticals
- Progenics Pharmaceuticals
- Protherics
- Reata Pharmaceuticals
- Receptor BioLogix
- Regeneron
- Regulon
- RESprotect
- Rexahn
- Rigel
- Samyang
- Sanofi-Aventis
- Santaris Pharma
- Sareum
- Scancell
- Seattle Genetics
- Semafore Pharmaceuticals
- ShimodaAtlantic Oncology
- Shire
- Sigma-Tau
- Silence Therapeutics
- Simcere Pharmaceuticals
- Sirnaomics
- SRI International
- SuperGen
- SuppreMol
- Supratek Pharma
- Switch Pharma
- Symbiotec
- Symphogen
- SynDevRx
- Synta Pharmaceuticals
- Taiho
- Takeda
- Talon Therapeutics
- Tapestry Pharmaceuticals
- Targa Therapeutics
- Taxolog
- TeGenero
- Tekmira Pharmaceuticals
- Telik
- Teva
- Thallion Pharmaceuticals
- Therion Biologics
- Theryte
- ThromboGenics
- Tigris Pharmaceuticals
- Titan Pharmaceuticals
- TopoTarget
- Tracon Pharmaceuticals
- Tragara Pharmaceuticals
- Transgene
- TriAct Therapeutics
- Trion Pharma
- UCB
- Vaccinex
- Valeant
- Vascular Biogenics
- Vaxon Biotech
- VaxOnco
- Vernalis
- Vertex Pharmaceuticals
- Vical
- Wilex
- Vion Pharmaceuticals
- VioQuest
- VioQuest Pharmaceuticals
- Viragen
- Viralytics
- ViroTarg
- Wyeth
- Xencor
- Xerion
- Xoma
- Yakult Honsha
- YM BioSciences
- Zhejiang Beta Pharma
- Zivena
- ZymoGenetics
Featured Drugs
A Shortlist of Drugs Included are:
- 131I-tositumomab
- 2-methoxyestradiol
- abagovomab
- ABT-263
- adecatumumab
- AEG-35156
- afatinib
- aflibercept
- afutuzumab
- AGS-1C4D4
- AGS-PSCA
- ALD-518
- alemtuzumab
- alvocidib
- ALXN-6000
- AME-133
- AMG-479
- amrubicin hydrochloride
- Apomab
- ARQ-197
- AS-1411
- astuprotimut-r
- atiprimod dimaleate
- ATN-224
- belagenpumatucel-L
- belinostat
- belotecan hydrochloride
- bevacizumab
- BIBF-1120
- BIIB-022
- blinatumomab
- BMS-663513
- brentuximab vedotin
- BZL-101
- canfosfamide hydrochloride
- catumaxomab
- CBLC-102
- celecoxib
- cenersen
- cetuximab
- cintredekin besudotox
- cixutumumab
- CNTO-328
- CNTO-888
- combretastatin A-4 prodrug
- conatumumab
- crizotinib
- CS-1008
- CT-011
- dacomitinib
- daratumumab
- denosumab
- DI-17E6
- docetaxel
- dulanermin
- elotuzumab
- EMD-273063
- emepepimut-S
- endostatin
- epratuzumab
- epratuzumab-Y90
- erlotinib
- ertumaxomab
- etoposide (1)
- etoposide phosphate
- F-50035
- farletuzumab
- figitumumab
- fresolimumab
- G-250
- galiximab
- GCS-100LE
- GDC-0449
- gefitinib
- GRN-163L
- HE-3235
- I-131-labetuzumab
- ibritumomab tiuxetan
- icotinib hydrochloride
- idronoxil
- IMC-3G3
- IMGN-901
- indisulam
- INGN-241
- INGN-401
- iniparib
- inotuzumab ozogamicin
- interferon (gamma1b)
- intetumumab
- IPH-2101
- ipilimumab
- iratumumab
- irinotecan hydrochloride
- ISIS-23722
- kahalalide F
- KW-0761
- L19-SIP
- lapatinib ditosylate
- lintuzumab
- LIP-131I
- lonaprisan
- lucatumumab
- lumiliximab
- lymphomun
- mapatumumab
- matuzumab
- MCS-110
- MDX-1106
- MGCD-0103
- milatuzumab
- MKC-1
- MM-111
- MORAb-009
- motesanib diphosphate
- motexafin gadolinium
- nadroparin
- naptumomab estafenatox
- natalizumab
- necitumumab
- nimotuzumab
- oblimersen sodium
- ocrelizumab
- ofatumumab
- Onyvax-105
- oregovomab
- paclitaxel
- paclitaxel polyglumex
- panitumumab
- panobinostat
- PARP inhibitors
- PAT-SC1
- patupilone
- pazopanib hydrochloride
- PCI-24781
- pemetrexed disodium
- pertuzumab
- PF-4856884
- plitidepsin
- quarfloxacin
- ramucirumab
- retaspimycin
- RG 3638
- RG-1507
- Rh-Apo2L
- rilotumumab
- rituximab
- robatumumab
- sagopilone
- seliciclib
- sorafenib tosylate
- talactoferrin alfa
- tegafur + uracil
- Tenarad
- thymalfasin
- tigapotide triflutate
- tigatuzumab
- TLN-232
- tocilizumab
- topotecan
- trastuzumab
- tremelimumab
- triciribine
- TRU-016
- TS-1
- tucotuzumab celmoleukin
- veltuzumab
- volociximab
- voreloxin
- VX-944
- XL-647
- YS-110
- yttrium Y 90 clivatuzumab tetraxetan
- zalutumumab
- Zemab
